Taysha Gene Therapies (TSHA) Assets Average (2020 - 2026)

Taysha Gene Therapies (TSHA) has 7 years of Assets Average data on file, last reported at $321.8 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 115.47% year-over-year to $321.8 million; the trailing twelve-month figure through Mar 2026 stood at $321.8 million (up 115.47% YoY), and the FY2025 full-year result was $251.8 million, up 51.21% from the prior year.
• Assets Average slipped to $321.8 million in Q1 2026, from $329.9 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $329.9 million in Q4 2025 to a low of $91.6 million in Q2 2023.
• A 5-year average of $187.1 million and a median of $170.3 million in 2024 frame the typical range for Assets Average.
• Across the five-year window, Assets Average slumped 47.75% in 2022 and soared 115.47% in 2026, its largest moves.
• Tracing TSHA's Assets Average over 5 years: stood at $118.9 million in 2022, then soared by 55.0% to $184.2 million in 2023, then fell by 7.58% to $170.3 million in 2024, then jumped by 93.75% to $329.9 million in 2025, then slipped by 2.46% to $321.8 million in 2026.
• Business Quant data shows TSHA's Assets Average at $321.8 million in Q1 2026, $329.9 million in Q4 2025, and $324.9 million in Q3 2025.